ライフサイエンスコーパス: angiosarcoma

1 mas, 0 of 1 hemangioendothelioma, and 0 of 1 angiosarcoma).

2 metastasis, were enriched in mouse and human angiosarcoma.

3 c changes underpinning primary and secondary angiosarcoma.

4 ogenesis signaling genes, as a key driver of angiosarcoma.

5 efforts to target angiogenesis signaling in angiosarcoma.

6 TAT3 pathway as a rational strategy to treat angiosarcoma.

7 istologically and genetically resemble human angiosarcoma.

8 t the radiologist to a possible diagnosis of angiosarcoma.

9 which are showing promise in the control of angiosarcomas.

10 ted in a variety of human cancers, including angiosarcomas.

11 carcinomas, MCF-7 breast carcinomas, and SVR angiosarcomas.

12 with particular susceptibility to aggressive angiosarcomas.

13 hich were histologically well-differentiated angiosarcomas.

14 iagnosis, followed by fibrosarcoma (15%) and angiosarcoma (15%).

15 ignant disorders other than KS and NHL, only angiosarcoma (36.7-fold), Hodgkin's disease (7.6-fold),

16 ng from the liver hemangiomas, and extremity angiosarcomas all occur at a rate of less than 10%.

17 utophosphorylation of VEGFR2 and reported in angiosarcomas alongside other driver mutations.

18 lobal pesticide poisoning outbreaks, hepatic angiosarcoma among vinyl chloride workers, toxic oil syn

19 role in the pathobiology of KS and cutaneous angiosarcoma and identify additional potential targets f

20 In this review we discuss angiosarcoma and its current management, with a focus on

21 receptors play a role in the pathobiology of angiosarcoma and KS, we studied the expression of angiop

22 ity when using MB(V) compared with MB(C) for angiosarcoma and malignant glioma tumors (P < .001).

23 or lines of therapy were treated (0 to 3 for angiosarcoma and malignant peripheral-nerve sheath tumor

24 single agent, sorafenib has activity against angiosarcoma and minimal activity against other sarcomas

25 V/HHV8 sequences were found in 7 of 24 (29%) angiosarcomas and 1 of 20 (5%) hemangiomas but not in an

26 Angiosarcomas and fibrohistiocytic tumors were most freq

27 sought to establish the molecular biology of angiosarcomas and identify specific targets for treatmen

28 uamous cell carcinomas, adenocarcinomas, and angiosarcomas), and induced by various chemical and phys

29 Kaposi's sarcoma (KS), 2 cases of cutaneous angiosarcoma, and 6 cases of capillary hemangioma by in

30 In comparison, leiomyoscarcomas, angiosarcomas, and fibrohistiocytic tumors comprised 16.

31 of angiopoietin-1 was seen in KS, cutaneous angiosarcomas, and in normal skin.

32 intravenously into nude mice (n = 4) bearing angiosarcomas, and the whole-body biodistribution of the

33 sociated Kaposi's sarcoma (KS) and cutaneous angiosarcoma are malignancies of endothelial origin.

34 sarcoma, malignant fibrous histiocytoma, and angiosarcoma are the most common types of sarcoma to occ

35 ronic lymphoedema and hence secondary breast angiosarcomas are an important subgroup.

36 Angiosarcomas are rare soft-tissue sarcomas of endotheli

37 Primary cardiac angiosarcomas are rare tumors with unfavorable prognosis

38 greater susceptibility to VC-induced hepatic angiosarcoma as well as their particular susceptibility

39 ous radiation therapy (RT)-associated breast angiosarcoma (AS) is a rare consequence of breast RT ass

40 Angiosarcoma (AS) is a rare understudied soft tissue sar

41 Angiosarcomas (AS) represent a heterogeneous group of ma

42 to paclitaxel once per week in treatment of angiosarcomas (AS).

43 Control studies in angiosarcoma-bearing mice were performed with injection

44 ecapitulate genetic traits observed in human angiosarcoma, but also unveil a possible therapeutic lin

45 Using a panel of hemangioendothelioma and angiosarcoma cell lines, we demonstrate that beta adrene

46 ling with propranolol hydrochloride disrupts angiosarcoma cell survival and xenograft angiosarcoma pr

47 pathway is required for soft agar growth of angiosarcoma cells, and separates the phenotypes of soft

48 dominant negative MAPKK gene into SVR murine angiosarcoma cells.

49 lation of ras-mediated tumor angiogenesis in angiosarcoma cells.

50 ully penetrant animal model for the study of angiosarcoma development and metastasis.

51 y in myeloid cells was insufficient to block angiosarcoma development; in contrast, systemic inhibiti

52 s underlying the activity of these agents in angiosarcoma, EHE, and HPC/SFT are poorly understood.

53 survival periods were generally low, several angiosarcoma, EHE, and HPC/SFT patients demonstrated res

54 effective therapy for certain patients with angiosarcoma, EHE, and HPC/SFT, but more studies are nee

55 th factor (VEGF) and its receptor (VEGFR) in angiosarcoma, epithelioid hemangioendothelioma (EHE), an

56 Angiosarcoma, epithelioid hemangioendothelioma, and Kapo

57 m 12 AIDS patients, in biopsies of cutaneous angiosarcoma from two patients, and in control biopsies

58 The angiosarcomas generated from MS1 VEGF cells demonstrated

59 f Ikkbeta, IL-6, or Stat3 markedly inhibited angiosarcoma growth.

60 ergic-positive multifocal stage T2 cutaneous angiosarcoma (>/=20 cm) involving 80% of the scalp, left

61 Five of 37 patients with angiosarcoma had a partial response (response rate, 14%)

62 Although human angiosarcoma has been associated frequently with mutatio

63 us benign and malignant disorders, including angiosarcoma, hemangiomas, and solid tumors.

64 g expression of KDR by tumor cells in KS and angiosarcoma implies that VPF/VEGF may also have a direc

65 first major advancement in the treatment of angiosarcoma in decades.

66 vinyl chloride (VC) clearly induces hepatic angiosarcoma in humans and rodents, a causal association

67 vivo, honokiol was highly effective against angiosarcoma in nude mice.

68 the outbred Black Swiss background and more angiosarcomas in 129/SvJae chimeric mice.

69 imaging, and pathologic findings of mammary angiosarcomas in 24 patients.

70 The presence of KSHV/HHV8 in angiosarcomas in addition to classical KS also indicates

71 Angiosarcomas in aP2-Cre;Dicer1(Flox/-) mice histologica

72 the groundwork for a promising treatment of angiosarcomas in humans.

73 ected in the tumor cells of KS and cutaneous angiosarcomas, in contrast to the focal low-level expres

74 ith aP2-Cre drives aggressive and metastatic angiosarcoma independent of other genetically engineered

75 g in LSECs leads to spontaneous formation of angiosarcoma, indicating its role as a tumor suppressor

76 Angiosarcoma is an aggressive malignancy that arises spo

77 Angiosarcoma is an aggressive vascular sarcoma with an e

78 Here we report that malignant angiosarcoma is associated with high levels of RelA/NF-k

79 on of signal output, which in papillomas and angiosarcomas is achieved via increased Hras-gene copy n

80 Angiosarcoma/lymphangiosarcoma is a rare malignancy with

81 troperitoneal leiomyosarcoma, osteosarcomas, angiosarcomas, malignant fibrous histiocytomas, malignan

82 Leiomyosarcoma and angiosarcoma may occur disproportionately in immunodefic

83 as appear causatively linked to EBV, whereas angiosarcomas might be correlated with an arteriovenous

84 vascular tumor growth was tested in a mouse angiosarcoma model, of which the tumor growth mimics the

85 logy database who had a diagnosis of mammary angiosarcoma (n = 26) and who underwent preoperative ima

86 patients treated overall and by subtype: two angiosarcomas (n = 16), 0 Ewing (n = 13), one fibrosarco

87 st frequently reported sarcomas, followed by angiosarcomas (n = 23) and fibrohistiocytic tumors (n =

88 rformed in 28 tumor-bearing nude mice (mouse angiosarcoma, n = 18; rat malignant glioma, n = 10).

89 for the development of the sentinel neoplasm angiosarcoma of the liver represent a model population f

90 cause specific p53 mutations in persons with angiosarcoma of the liver.

91 Angiosarcoma of the spleen could be suggested in the maj

92 Records of 12 cases of proved angiosarcoma of the spleen were accessed from the files

93 Patients with stage T2 multilesion angiosarcomas of the scalp and face that are larger than

94 nd developed portal hypertension and hepatic angiosarcoma over time.

95 pts angiosarcoma cell survival and xenograft angiosarcoma progression.

96 at beta-blockade alone substantially reduced angiosarcoma proliferation and, in combination with stan

97 lar tumors such as hemangioendotheliomas and angiosarcomas, revealing beta 1, 2, and 3 receptors were

98 GF, HIF1alpha, and c-Myc expression in human angiosarcoma samples.

99 set of nonhematolymphoid neoplasms including angiosarcoma, solitary fibrous tumors, epithelioid sarco

100 imary, lymphoma, gastric, duodenal, bladder, angiosarcoma, squamous cell carcinoma, thyroid, adrenal,

101 Tumor cells in KS and angiosarcoma strongly expressed KDR but not flt-1 mRNA.

102 dorsal aorta and is reactivated in malignant angiosarcoma, suggesting a strong association of Wnt1 wi

103 The tumor type was angiosarcoma, suggesting that vascular tissues are predi

104 pecificity on cells expressing VEGFR2 (mouse angiosarcoma SVR cells) and control cells (mouse skeleta

105 its presence in a significant proportion of angiosarcomas, this study extends the number of tumors a

106 e regulation of AMF-R expression in a BALB/c angiosarcoma tumor system that allows investigation of c

107 Some angiosarcoma tumors, however, harbor specific activating

108 as a single agent in reducing the growth of angiosarcoma tumors.

109 The presence of the virus in angiosarcoma was confirmed by direct sequencing of the p

110 carcinomas, 10 normal breast tissues, and 16 angiosarcomas were included.

111 These mice developed papillomas and angiosarcomas, which were associated with Hras(G12V) all

112 ven links between vascular malformations and angiosarcoma with activated Ras signaling, we sought to

113 expression and response in six patients with angiosarcoma with paired pre- and post-therapy biopsies.

114 LCgamma1 signaling besides KDR activation in angiosarcomas, with implications for VEGF/KDR targeted t

115 utility of treating vascular tumors, such as angiosarcomas, with S6K inhibitors.

116 olimus 3 mg/kg/d inhibited the growth of SVR angiosarcoma xenografts in mice by 46% (P = 0.04).